Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SR 703Sesión 89R

Qué cambió entre versiones

236 párrafos cambiaron+296 palabras agregadas−273 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

89R34544 CJD-D

By: Parker

S.R. No. 703

RSENATE E S O L U T I O NRESOLUTION

BE IT RESOLVED by the Senate of the State of Texas, 89th

Legislature, Regular Session, 2025, That Senate Rule 12.03 be

suspended in part as provided by Senate Rule 12.08 to enable the

conference committee appointed to resolve the differences on Senate

Senate Bill 2308 (the establishment of a consortium to conduct United

United States Food and Drug Administration's drug development clinical

clinical trials with ibogaine to secure the administration's approval of the

approval of the medication's use for treatment of opioid use disorder, co-occurring

disorder, co-occurring substance use disorder, and any other neurological or mental health

neurological or mental health conditions for which ibogaine

conditions for which ibogaine demonstrates efficacy and to the administration of that

administration of that treatment) to consider and take action on the following matters:

the following matters:

(1) Senate Rule 12.03(2) is suspended to permit the

committee to omit text not in disagreement by omitting in proposed

proposed SECTION 1 of the bill added Section 491.001(2), Health and Safety

and Safety Code. The omitted text reads:

(2) "Executive commissioner" means the executive

commissioner of the Health and Human Services Commission.

Explanation: The change is necessary to remove a definition

definition that no longer appears in added Chapter 491, Health and Safety Code.

and Safety Code.

(2) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding Sections 491.001(2), (3), (4), and (6), Health and Safety

Safety Code, to read as follows:

(2) "Comptroller" means the comptroller of public

accounts.

(3) "Drug developer" means a pharmaceutical company,

company, biotechnology company, or contract development and manufacturing

manufacturing organization engaged in drug development and manufacturing.

manufacturing.

(4) "Hospital" has the meaning assigned by Section

241.003.

(6) "Institution of higher education" has the meaning

meaning assigned by Section 61.003, Education Code.

Explanation: The change is necessary to define

3 párrafos sin cambios

"comptroller," "drug developer," "hospital," and "institution of

higher education" for purposes of added Chapter 491, Health and

Safety Code.

(3) Senate Rule 12.03(2) is suspended to permit the

committee to omit text not in disagreement in proposed SECTION 1 of

of the bill by omitting added Sections 491.002 and 491.003, Health and

Health and Safety Code. The omitted text reads:

Sec. 491.002. RULES. The executive commissioner shall

adopt rules necessary to administer this chapter.

Sec. 491.003. ESTABLISHMENT OF GRANT PROGRAM. The

commission shall establish and administer a grant program to fund a

a public-private partnership program that will pay for the costs of

of the United States Food and Drug Administration's drug development

development trials with ibogaine to secure the administration's approval as a

approval as a medication for treatment of opioid use disorder, co-occurring

co-occurring substance use disorder, and any other neurological or mental health

or mental health conditions for which ibogaine demonstrates efficacy.

efficacy.

Explanation: The change is necessary to eliminate rulemaking

rulemaking authority and remove a grant program.

(4) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding a heading for added Subchapter B, Chapter 491, Health and

and Safety Code, to read as follows:

SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT

Explanation: The change is necessary for better organization

organization of added Chapter 491, Health and Safety Code.

(5) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding Sections 491.051 and 491.052, Health and Safety Code, to

to read as follows:

Sec. 491.051. ESTABLISHMENT OF CONSORTIUM. (a) A

6 párrafos sin cambios

consortium may be established under this section and apply for

commission selection under this subchapter to conduct drug

development clinical trials with ibogaine and secure the United

States Food and Drug Administration's approval of ibogaine as a

medication for the treatment of:

(1) opioid use disorder;

(2) co-occurring substance use disorder; and

(3) any other neurological or mental health condition

condition for which ibogaine demonstrates efficacy.

(b) A consortium established under this section must

3 párrafos sin cambios

include one or more of each of the following entities:

(1) a drug developer;

(2) an institution of higher education; and

(3) a hospital.

Sec. 491.052. LEAD INSTITUTION; ADMINISTRATION; PERSONNEL.

PERSONNEL. (a) A consortium established under this subchapter shall select a

shall select a lead institution of higher education from among the consortium's

the consortium's members to represent the consortium and perform administrative

administrative functions under this subchapter, including contracting with and

contracting with and reporting to the commission as required by this subchapter.

this subchapter.

(b) A consortium selected by the commission under this

3 párrafos sin cambios

subchapter may employ personnel, including clinical,

administrative, and data management personnel, necessary to

support any consortium member's activities related to drug

development clinical trials conducted under this subchapter.

Explanation: The change is necessary to allow formation of a

of a consortium for the conduct of certain drug development clinical

clinical trials, to secure United States Food and Drug Administration's

Administration's approval for certain medical treatments, and to allow the

allow the consortium to select a lead institution and employ necessary

necessary personnel.

(6) Senate Rule 12.03(2) is suspended to permit the

committee to omit text not in disagreement in proposed SECTION 1 of

of the bill by omitting the heading and Subsections (a) and (c) of

added Section 491.004, Health and Safety Code. The omitted text

5 párrafos sin cambios

reads:

Sec. 491.004. APPLICATION. (a) The commission shall

prepare and issue a notice of funding opportunity to solicit

applications for the grant program established under this

subchapter.

(c) The commission shall:

(1) make available the application required under this

this section; and

(2) announce a period of not less than 90 days during

during which applicants may submit an application under this subchapter.

subchapter.

Explanation: The change is necessary to remove an

application process for a removed grant program.

(7) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding a heading and Subsection (a) for Section 491.053, Health and

Health and Safety Code, to read as follows:

Sec. 491.053. CONSORTIUM PROPOSAL. (a) The lead

institution of higher education of a consortium shall submit to the

the commission a proposal and request for funding on behalf of the

the consortium for purposes of conducting ibogaine drug development

development clinical trials in accordance with this subchapter.

Explanation: The change is necessary to require a consortium

consortium formed under added Chapter 491, Health and Safety Code, to submit to

Code, to submit to the Health and Human Services Commission a proposal for selection

proposal for selection to conduct a drug development clinical trial under that chapter.

trial under that chapter.

(8) Senate Rules 12.03(1), (2), and (3) are suspended to

4 párrafos sin cambios

permit the committee to change, alter, or amend text not in

disagreement, omit text not in disagreement, and add text on a

matter not in disagreement in proposed SECTION 1 of the bill, by

adding Section 491.053(b), Health and Safety Code, to read as

follows:

(b) A proposal submitted under Subsection (a) must provide:

provide:

(1) the identity of all consortium members;

(2) a detailed description of the planned strategy for

for obtaining approval for the drug development clinical trials from

from the United States Food and Drug Administration;

(3) a detailed drug development clinical trial design

design that includes:

(A) a description of the composition of the

consortium's drug development clinical trial team and the expertise

expertise of the team members;

(B) a drug development clinical trial

19 párrafos sin cambios

participant recruitment plan;

(C) patient screening criteria and cardiac

safety protocols;

(D) administration protocols;

(E) an aftercare and post-acute treatment

support plan; and

(F) a data integrity plan;

(4) a detailed plan to seek a breakthrough therapy

designation for ibogaine from the United States Food and Drug

Administration under 21 U.S.C. Section 356;

(5) a proposal to recognize this state's commercial

interest in all intellectual property that may be generated over

the course of the drug development clinical trials, including:

(A) the treatment that is the subject of the

trials;

(B) administration protocols;

(C) treatment models or techniques; and

(D) technology used in the trials;

(6) a plan to establish a corporate presence in this

state and to promote and maintain ibogaine-related biomedical

research, development, treatment, manufacturing, and distribution

distribution in this state;

(7) a plan to secure third-party payor approval for

ibogaine treatment following approval by the United States Food and

and Drug Administration through:

(A) private insurers;

4 párrafos sin cambios

(B) Medicare;

(C) Medicaid; and

(D) the TRICARE program of the United States

Department of Defense;

(8) a plan to ensure ibogaine treatment access to

uninsured individuals following approval by the United States Food

Food and Drug Administration;

(9) a plan to train and credential medical providers

10 párrafos sin cambios

to administer ibogaine treatment according to developed clinical

standards; and

(10) financial disclosures that verify the

consortium's capacity to fully match state funding with funds

received from non-state sources.

Explanation: The change is necessary to specify the

information required for submission of a proposal under Section

491.053, Health and Safety Code, and selection to perform drug

development clinical trials under added Chapter 491, Health and

Safety Code.

(9) Senate Rule 12.03(2) is suspended to permit the

committee to omit text not in disagreement in proposed SECTION 1 of

of the bill by omitting added Section 491.005, Health and Safety Code.

Code. The omitted text reads:

Sec. 491.005. SELECTION COMMITTEE. (a) The commission

5 párrafos sin cambios

shall create a selection committee and select the number of

members. The committee must be composed of:

(1) subject matter experts;

(2) philanthropic partners; and

(3) legislative designees.

(b) The selection committee shall review applications,

communicate supplemental inquiries to applicants, and recommend to

to the commission the best applicants to conduct the drug development

development trials.

(c) The commission shall consider the recommendations of

the selection committee in selecting the applicant to conduct the

ibogaine drug development trial.

Explanation: The change is necessary to remove the selection

selection committee.

(10) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding Sections 491.054 and 491.055, Health and Safety Code, to

to read as follows:

Sec. 491.054. COMMISSION SELECTION. The commission, in the

the commission's sole discretion, shall select a consortium

established in accordance with Section 491.051 for the purpose of

conducting ibogaine drug development clinical trials under this

subchapter.

Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As soon

soon as practicable after selecting a consortium to conduct ibogaine

ibogaine drug development clinical trials under Section 491.054, the

the commission shall enter into an interagency contract, as provided by

provided by Chapter 771, Government Code, with the lead institution of higher

institution of higher education of the selected consortium to provide funding to

provide funding to implement the consortium's proposed ibogaine drug development

drug development clinical trials.

(b) The interagency contract described by Subsection (a)

must specify:

(1) the goals and objectives of the proposed ibogaine

ibogaine drug development clinical trials;

(2) the proposed budget;

6 párrafos sin cambios

(3) the timeline for completing the proposed

objectives;

(4) the for-profit, nonprofit, or public benefit

corporate entities collaborating with the consortium in the drug

development clinical trials under this subchapter;

(5) the percentage of the revenue arising from the

drug development clinical trials to be paid to the state; and

(6) any other information required by the commission.

commission.

(c) As soon as practicable after entering into an

4 párrafos sin cambios

interagency contract under Subsection (a), the commission shall

report the existence of the contract to the legislature.

(d) The commission may not disburse funds to or for a

selected consortium under the interagency contract described by

Subsection (a) until the consortium receives and the commission

verifies the receipt of matching funds from sources other than the

the state.

Explanation: The change is necessary to allow the Health and

and Human Services Commission to select a consortium established under

under added Chapter 491, Health and Safety Code, for the purpose of

of conducting drug development clinical trials under that chapter, to

chapter, to require the commission to enter into an interagency contract with

contract with the consortium for the conduct of those trials, and to regulate the

to regulate the contract provisions and the disbursement of funds to the selected

to the selected consortium.

(11) Senate Rules 12.03(1) and (3) are suspended to permit

permit the committee to change, alter, or amend text not in disagreement

disagreement and add text on a matter not in disagreement in proposed SECTION 1

proposed SECTION 1 of the bill, by adding Section 491.056, Health and Safety Code, to

and Safety Code, to read as follows:

Sec. 491.056. INVESTIGATIONAL NEW DRUG APPLICATION. On the

the commission's notification that a consortium is selected to conduct

conduct the drug development clinical trials under this subchapter, a drug

subchapter, a drug developer or hospital member of the selected consortium or the lead

consortium or the lead institution of higher education of the consortium, as specified by

consortium, as specified by written agreement of the consortium members, shall, as soon as

members, shall, as soon as practicable:

(1) submit an investigational new drug (IND)

application to the United States Food and Drug Administration in

accordance with 21 C.F.R. Part 312; and

(2) seek a breakthrough therapy designation for

ibogaine from the United States Food and Drug Administration under

under 21 U.S.C. Section 356.

Explanation: The change is necessary to allow certain

members of a consortium established under added Chapter 491, Health

Health and Safety Code, to apply for an investigational new drug

application with the United States Food and Drug Administration and

and to seek from the administration a breakthrough therapy designation

designation for certain treatments.

(12) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding Section 491.057, Health and Safety Code, to read as follows:

follows:

Sec. 491.057. DRUG DEVELOPMENT CLINICAL TRIAL SITES. For

SITES. For purposes of conducting a drug development clinical trial under this

trial under this subchapter, only an institution of higher education or a hospital

education or a hospital may serve as a trial site.

Explanation: The change is necessary to specify which

members of a consortium established under added Chapter 491, Health

Health and Safety Code, may serve as a drug development clinical trial site

trial site under that chapter.

(13) Senate Rule 12.03(2) is suspended to permit the

committee to omit text not in disagreement in proposed SECTION 1 of

of the bill by omitting added Sections 491.007 and 491.008, Health and

Health and Safety Code. The omitted text reads:

Sec. 491.007. ESTABLISHMENT OF DRUG DEVELOPMENT TRIAL

SITES. On approval of the applicant's investigational new drug

application by the United States Food and Drug Administration, the

the commission shall, in consultation with the applicant, establish

establish drug development trial sites that must be equipped and staffed to

staffed to provide cardiac intensive care services to patients.

Sec. 491.008. CONDUCTING DRUG DEVELOPMENT TRIAL. (a) As

soon as practicable after drug development trial sites are

established under Section 491.007, the applicant shall begin a drug

drug development trial to administer treatment with ibogaine.

(b) The commission, in consultation with the selection

committee under Section 491.005, shall select an institutional

review board with a presence in this state to oversee and verify the

the drug development trial research activity for scientific validation

validation and authentication under the requirements of the United States Food

United States Food and Drug Administration.

(c) The applicant shall request the designation under 21

U.S.C. Section 356 during the drug development trial if the

ibogaine treatment is demonstrating efficacy.

Explanation: The change is necessary to remove requirements

requirements relating to drug development trial sites and the conduct of a drug

conduct of a drug development trial.

(14) Senate Rules 12.03(1), (2), and (4) are suspended to

permit the committee to change, alter, or amend text not in

disagreement, omit text on a matter not in disagreement, and add

text on a matter not included in either the house or senate version

version of the bill in proposed SECTION 1 of the bill, by adding Section

Section 491.058, Health and Safety Code, to read as follows:

Sec. 491.058. FUNDING; DISBURSEMENT BY COMMISSION. (a)

The commission and consortium members may solicit and accept gifts,

gifts, grants, and donations of any kind received from sources other than

other than the state for purposes of funding drug development clinical trials

clinical trials under this subchapter.

(b) Disbursements of funds by the commission may be made

incrementally based on the completion of clearly defined objectives

objectives as negotiated in the contract described by Section 491.055,

491.055, including verifiable documentation demonstrating the efficient

efficient expenditure of both state and matching funds.

Explanation: The change is necessary to clarify that

3 párrafos sin cambios

matching funds provided by a consortium established under added

Chapter 491, Health and Safety Code, must come from sources other

than the state, and to add accountability requirements.

(15) Senate Rule 12.03(2) is suspended to permit the

committee to omit text not in disagreement in proposed SECTION 1 of

of the bill by omitting added Section 491.009(b), Health and Safety

Safety Code. The omitted text reads:

(b) An applicant selected to perform a drug development

4 párrafos sin cambios

trial under this subchapter shall contribute toward the cost of

developing the ibogaine treatment an amount of money that is at

least equal to the amount of money that the applicant received in

the form of a grant from the commission.

Explanation: The change is necessary to eliminate

duplicative and conflicting provisions relating to matching funds.

funds.

(16) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 1 of the bill, by

by adding Sections 491.059, 491.060, and 491.061, Health and Safety

Safety Code, to read as follows:

Sec. 491.059. REPORTING REQUIREMENTS. (a) A consortium

selected to conduct ibogaine drug development clinical trials shall

shall quarterly prepare and submit to the commission:

(1) a report on the progress of the drug development

clinical trials conducted under this subchapter; and

(2) a financial status report, including information

information to verify expenditures of state funds and required matching funds.

matching funds.

(b) The commission shall submit a report to the legislature

legislature on the progress of the drug development clinical trials conducted

trials conducted under this subchapter not later than December 1 of each year.

of each year.

Sec. 491.060. ALLOCATION OF REVENUE ATTRIBUTABLE TO

5 párrafos sin cambios

INTELLECTUAL PROPERTY AND OTHER RIGHTS. (a) The revenue

attributable to all intellectual property rights and other

commercial rights arising from drug development clinical trials

conducted by a consortium under this subchapter during the period

for which the trials are funded and any following period of

commercialization shall be allocated as follows:

(1) not less than 20 percent to the state as specified

specified in the contract under Section 491.055; and

(2) the remainder to the members of the consortium in

in the amounts specified by written agreement of the members.

(b) For purposes of this section, intellectual property

14 párrafos sin cambios

rights and other commercial rights arising from the drug

development clinical trials conducted under this subchapter

include any of the following as related to the trials:

(1) intellectual property, technology, and

inventions;

(2) patents, trademarks, and licenses;

(3) proprietary and confidential information;

(4) trade secrets, data, and databases;

(5) tools, methods, and processes;

(6) treatment models or techniques;

(7) administration protocols; and

(8) works of authorship.

Sec. 491.061. USE OF STATE REVENUE. (a) The comptroller

shall deposit the revenue received under Section 491.060 to the

credit of the general revenue fund.

(b) Of the amount deposited under Subsection (a), 25 percent

percent may be appropriated only to programs that assist veterans in this

in this state.

(c) The comptroller shall develop accounting procedures for

for the purpose of implementing this section.

Explanation: The change is necessary to establish reporting

reporting requirements for a consortium established under added Chapter 491,

Chapter 491, Health and Safety Code, and to clarify the allocation of revenues

allocation of revenues attributable to certain property rights under that chapter.

under that chapter.

(17) Senate Rule 12.03(4) is suspended to permit the

committee to add text on a matter not included in either the house

or senate version of the bill in proposed SECTION 2 of the bill, by

by adding Subsection (b) to read as follows:

(b) The Health and Human Services Commission shall begin

accepting proposals from consortiums under Chapter 491, Health and

and Safety Code, as added by this Act, not later than the 60th day after

after the effective date of this Act.

Explanation: The change is necessary to require the Health

Health and Human Services Commission to begin accepting proposals from

proposals from consortiums under added Chapter 491, Health and Safety Code, by a

Safety Code, by a certain date.

_______________________________

President of the Senate

I hereby certify that the

above Resolution was adopted by

the Senate on May 31, 2025, by the

following vote: Yeas 31, Nays 0.

_______________________________

Secretary of the Senate

Volver al texto completo